Search Results - "Kunz, Arthur"

Selection of Reaction Additives Used in the Preparation of Monomeric Antibody−Calicheamicin Conjugates by Hollander, Irwin, Kunz, Arthur, Hamann, Philip. R

“…The formation of protein aggregates can be a major problem during the preparation of antibody−drug conjugates. Herein is described the methods by which…”
Get full text

Potent and Specific Antitumor Efficacy of CMC-544, a CD22-Targeted Immunoconjugate of Calicheamicin, against Systemically Disseminated B-Cell Lymphoma by DIJOSEPH, John F, GOAD, Mary E, DOUGHER, Maureen M, BOGHAERT, Erwin R, KUNZ, Arthur, HAMANN, Philip R, DAMLE, Nitin K

“…Purpose: CMC-544 is a CD22-targeted immunoconjugate of calicheamicin and exerts a potent cytotoxic effect against CD22 + B-cell lymphoma. This study evaluated…”
Get full text

CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab by Dijoseph, John F, Dougher, Maureen M, Armellino, Douglas C, Kalyandrug, Lyka, Kunz, Arthur, Boghaert, Erwin R, Hamann, Philip R, Damle, Nitin K

“…Tumor-targeted delivery of a potent cytotoxic agent, calicheamicin, using its immunoconjugates is a clinically validated therapeutic strategy. Rituximab is a…”
Get full text

Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22 by DIJOSEPH, John F, POPPLEWELL, Andrew, ZINKEWICH-PEOTTI, Karen, STEPHENS, Sue, WEIR, Neil, DAMLE, Nitin K, TICKLE, Simon, LADYMAN, Heather, LAWSON, Alastair, KUNZ, Arthur, KHANDKE, Kiran, ARMELLINO, Douglas C, BOGHAERT, Erwin R, HAMANN, Philip R

“…Antibody-targeted chemotherapy with immunoconjugates of calicheamicin is a clinically validated strategy in cancer therapy. This study describes the selection…”
Get full text

Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs by Andreev, Julian, Thambi, Nithya, Perez Bay, Andres E, Delfino, Frank, Martin, Joel, Kelly, Marcus P, Kirshner, Jessica R, Rafique, Ashique, Kunz, Arthur, Nittoli, Thomas, MacDonald, Douglas, Daly, Christopher, Olson, William, Thurston, Gavin

“…The properties of cell surface proteins targeted by antibody-drug conjugates (ADCs) have not been fully exploited; of particular importance are the rate of…”
Get full text

Abstract P134: Novel EGFRvIII-selective antibody-drug conjugate REGN3124-PBD is strongly efficacious against orthotopic glioblastoma multiforme patient derived xenografts by Kelly, Marcus P., Makonnen, Sosina, Hickey, Carlos, Mao, Shu, Zhao, Feng, Kunz, Arthur, Delfino, Frank, Nittoli, Thomas, Ma, Dangshe, Olson, William C., Thurston, Gavin, Kirshner, Jessica R.

“…Abstract Glioblastoma Multiforme (GBM) is a highly aggressive cancer with few specific molecular targets and poor therapeutic outcome. Epidermal Growth Factor…”
Get full text

A Biparatopic Antibody-Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade by DaSilva, John O, Yang, Katie, Surriga, Oliver, Nittoli, Thomas, Kunz, Arthur, Franklin, Matthew C, Delfino, Frank J, Mao, Shu, Zhao, Feng, Giurleo, Jason T, Kelly, Marcus P, Makonnen, Sosina, Hickey, Carlos, Krueger, Pamela, Foster, Randi, Chen, Zhaoyuan, Retter, Marc W, Slim, Rabih, Young, Tara M, Olson, William C, Thurston, Gavin, Daly, Christopher

“…Lung cancers harboring mesenchymal-to-epithelial transition factor ( ) genetic alterations, such as exon 14 skipping mutations or high-level gene…”
Get full text

Abstract 2898: A biparatopic HER2xHER2 antibody drug conjugate with potent anti-tumor activity by Bay, Andres Perez, Faulkner, Devon, Tiwari, Shiwani, Castanaro, Carla, Zheng, Xiang, Kunz, Arthur, Nittoli, Thomas, Han, Amy, Olson, William, Thurston, Gavin, Daly, Christopher, Andreev, Julian

“…Abstract A biparatopic HER2xHER2 antibody drug conjugate with potent anti-tumor activity. The antibody drug conjugate (ADC) Trastuzumab-emtansine (T-DM1)…”
Get full text

Antibody-Targeted Chemotherapy with the Calicheamicin Conjugate hu3S193-N-Acetyl γ Calicheamicin Dimethyl Hydrazide Targets Lewisy and Eliminates Lewisy-Positive Human Carcinoma Cells and Xenografts by BOGHAERT, Erwin R, SRIDHARAN, Latha, FROST, Philip, DAMLE, Nitin K, ARMELLINO, Douglas C, KHANDKE, Kiran M, DIJOSEPH, John F, KUNZ, Arthur, DOUGHER, Maureen M, JIANG, Fan, KALYANDRUG, Lyka B, HAMANN, Philip R

“…Purpose: Linking a cytotoxic anticancer drug to an antibody that recognizes a tumor-associated antigen can improve the therapeutic index of the drug. We asked…”
Get full text

Calicheamicin Derivatives Conjugated to Monoclonal Antibodies:  Determination of Loading Values and Distributions by Infrared and UV Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry and Electrospray Ionization Mass Spectrometry by Siegel, Marshall M, Tabei, Keiko, Kunz, Arthur, Hollander, Irwin J, Hamann, Philip R, Bell, Duncan H, Berkenkamp, Stefan, Hillenkamp, Franz

“…Calicheamicin derivatives (MW ∼1500) and monoclonal antibodies (MoAbs) conjugated to calicheamicin derivatives (MW ∼150 000) were analyzed by UV-MALDI/MS,…”
Get full text

Antibody drug conjugates of cleavable amino-benzoyl-maytansinoids by Nittoli, Thomas, Delfino, Frank, Kelly, Marcus, Carosso, Serena, Markotan, Thomas, Kunz, Arthur, Chen, Zhaoyuan, Mao, Shu, Shan, Jing, Navarro, Elizabeth, Zhao, Feng, Makonnen, Sosina, Hickey, Carlos, Spink, Jan, Olson, William, Kirshner, Jessica R., Thurston, Gavin, Papadopoulos, Nicholas

“…[Display omitted] ADCs based on the natural product maytansine have been successfully employed clinically. In a previous report, ADCs based on hydrophilic…”
Get full text

Antibody drug conjugates of cleavable amino-alkyl and aryl maytansinoids by Nittoli, Thomas, Kelly, Marcus P., Delfino, Frank, Rudge, John, Kunz, Arthur, Markotan, Thomas, Spink, Jan, Chen, Zhaoyuan, Shan, Jing, Navarro, Elizabeth, Tait, Michele, Provoncha, Kathleen, Giurleo, Jason, Zhao, Feng, Jiang, Xiaobo, Hylton, Donna, Makonnen, Sosina, Hickey, Carlos, Kirshner, Jessica R., Thurston, Gavin, Papadopoulos, Nicholas

“…[Display omitted] Natural products have been used for many medicinal purposes for centuries. Antibody drug conjugates (ADCs) have utilized this rich source of…”
Get full text

Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody-Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers by Kelly, Marcus P, Hickey, Carlos, Makonnen, Sosina, Coetzee, Sandra, Jalal, Sumreen, Wang, Yu, Delfino, Frank, Shan, Jing, Potocky, Terra B, Chatterjee, Ishita, Andreev, Julian, Kunz, Arthur, D'Souza, Christopher, Giurleo, Jason T, Nittoli, Thomas, Trail, Pamela A, Thurston, Gavin, Kirshner, Jessica R

“…The Prolactin Receptor (PRLR) is a type 1 cytokine receptor that is expressed in a subset of breast cancers and may contribute to its pathogenesis. It is…”
Get full text

Delineation of a Cellular Hierarchy in Lung Cancer Reveals an Oncofetal Antigen Expressed on Tumor-Initiating Cells by DAMELIN, Marc, GELES, Kenneth G, BEHRENS, Carmen, CHOE, Sung E, RIOS, Carol, GRUZAS, Janet, SRIDHARAN, Latha, DOUGHER, Maureen, KUNZ, Arthur, HAMANN, Philip R, EVANS, Deborah, ARMELLINO, Douglas, FOLLETTIE, Maximillian T, KHANDKE, Kiran, MARQUETTE, Kimberly, TCHISTIAKOVA, Lioudmila, BOGHAERT, Erwin R, ABRAHAM, Robert T, WISTUBA, Ignacio I, ZHOU, Bin-Bing S, PING YUAN, BAXTER, Michelle, GOLAS, Jonathon, DIJOSEPH, John F, KARNOUB, Maha, SHUGUANG HUANG, DIESL, Veronica

“…Poorly differentiated tumors in non-small cell lung cancer (NSCLC) have been associated with shorter patient survival and shorter time to recurrence following…”
Get full text

Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies by DiJoseph, John F., Armellino, Douglas C., Boghaert, Erwin R., Khandke, Kiran, Dougher, Maureen M., Sridharan, Latha, Kunz, Arthur, Hamann, Philip R., Gorovits, Boris, Udata, Chandrasekhar, Moran, Justin K., Popplewell, Andrew G., Stephens, Sue, Frost, Philip, Damle, Nitin K.

“…Antibody-targeted chemotherapy with gemtuzumab ozogamicin (CMA-676, a CD33-targeted immunoconjugate of N-acetyl-γ-calicheamicin dimethyl hydrazide [CalichDMH],…”
Get full text

Abstract C126: PRLR ADC: A novel antibody drug-conjugate for the treatment of PRLR positive breast cancer by Kelly, Marcus P., Coetzee, Sandra, Hickey, Carlos, Makonnen, Sosina, Delfino, Frank, Andreev, Julian, Kunz, Arthur, D'Souza, Christopher, Giurleo, Jason, Nittoli, Thomas, Trail, Pamela A., Papadopoulos, Nicholas, Thurston, Gavin, Kirshner, Jessica R.

“…Abstract Breast cancer is a heterogeneous disease comprised of various subtypes based on pathology and molecular profiling. Expression of hormone receptors…”
Get full text

Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 μl) blood samples by Boghaert, Erwin R., Khandke, Kiran M., Sridharan, Latha, Dougher, Maureen, DiJoseph, John F., Kunz, Arthur, Hamann, Philip R., Moran, Justin, Chaudhary, Inder, Damle, Nitin K.

“…Purpose The present study aims to establish a method that provides fast, precise and reproducible pharmacokinetic (PK) parameters of antibody-calicheamicin…”
Get full text

Abstract 475: Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cells by Damelin, Marc I., Geles, Kenneth G., Follettie, Maximillian T., Yuan, Ping, Baxter, Michelle, Golas, Jonathon, Huang, Shuguang, DiJoseph, John, Diesl, Veronica, Behrens, Carmen, Choe, Sung E., Rios, Carol, Gruzas, Janet, Sridharan, Latha, Dougher, Maureen, Kunz, Arthur, Hamann, Philip R., Evans, Deborah, Armellino, Douglas, Khandke, Kiran, Marquette, Kimberly, Tchistiakova, Lioudmila, Boghaert, Erwin, Abraham, Robert T., Wistuba, Ignacio I., Zhou, Bin-Bing S.

“…Abstract Poorly differentiated tumors in non-small cell lung cancer (NSCLC) are refractory to chemotherapy and associated with short survival time. Here we…”
Get full text

Tumoricidal effect of calicheamicin immuno-conjugates using a passive targeting strategy by BOGHAERT, Erwin R, KHANDKE, Kiran, DISCAFANI, Carolyn, DAMLE, Nitin K, SRIDHARAN, Latha, ARMELLINO, Douglas, DOUGHER, Maureen, DIJOSEPH, John F, KUNZ, Arthur, HAMANN, Philip R, SRIDHARAN, Ashwin, JONES, Stanley

“…Calicheamicin is a potent chemotherapeutic with a low therapeutic index that requires targeting to tumor cells for its use in the clinic. To treat acute…”
Get full text

B-cell depletion inhibits arthritis in a collagen-induced arthritis (CIA) model, but does not adversely affect humoral responses in a respiratory syncytial virus (RSV) vaccination model by Dunussi-Joannopoulos, Kyri, Hancock, Gerald E., Kunz, Arthur, Hegen, Martin, Zhou, Xiaochuan X., Sheppard, Barbara J., Lamothe, Jennifer, Li, Evelyn, Ma, Hak-Ling, Hamann, Philip R., Damle, Nitin K., Collins, Mary

“…We report the development of a mouse B cell-depleting immunoconjugate (anti-CD22 monoclonal antibody [mAb] conjugated to calicheamicin) and its in vivo use to…”
Get full text